This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Hospitals and health systems are rapidly expanding their internal specialtypharmacies—and they’re using questionable tactics to boost revenues and profits. Nearly two-thirds of the larger health system specialtypharmacies operate as the exclusive pharmacy within self-insured health systems’ networks.
Hospitals and health systems are building a major presence in the specialtypharmacy industry. As we demonstrate below, nine out of ten large hospitals now operate a specialtypharmacy. Hospitals and other healthcare providers account for one-third of all U.S. accredited specialtypharmacies.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone!
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers. to 1:30 p.m.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B DrugPricing Program: Trends, Controversies, and Outlook. billion figure was roughly accurate for the AllianceRx Walgreens Pharmacy business. Click here to see the original post from April 2024. All rights reserved.
pharmacies now participate in the 340B DrugPricing Program. Below, we update our exclusive analysis of the biggest specialtypharmacies within 340B. As you will see below, these specialtypharmacies have dramatically increased their participation in the 340B program.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone!
Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Fein, Ph.D., All rights reserved.
The stunning growth of specialtypharmacies in the 340B DrugPricing Program has accelerated a troubling trend: Patients covered by commercial insurance and Medicare Part D are footing the bill for 340B savings. Our indisputable math exposes the little-understood economics behind specialtypharmacies in the 340B program.
Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Fein, Ph.D., All rights reserved.
Fein will share his latest thinking on a wide range of topics, including: Retail and specialtypharmacy trends Vertical integration and consolidation The Inflation Reduction Act of 2022 The Medicare Part D Redesign Biosimilars Discount cards and cash-pay pharmacies The growing impact of hospitals and health systems The 340B DrugPricing Program Federal (..)
For more information on any aspect of developing & managing a successful 340B program AND/OR retail and specialtypharmacies, contact: HOWARD HALL C: 214.808.2700 | howard.hall@proxsysrx.com FULL POST According to a graphic published on its website, in 2023 Johnson & Johnson provided $42.8
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers. to 1:30 p.m.
Court of Appeals for the Third Circuit — which was largely in favor of three drug companies that have imposed harmful limits on safety-net hospitals’ access to 340B drugpricing program discounts. 340B revenues for numerous covered entities has plummeted.
Court of Appeals for the Third Circuit — which was largely in favor of three drug companies that have imposed harmful limits on safety-net hospitals’ access to 340B drugpricing program discounts. 340B revenues for numerous covered entities has plummeted.
Nowhere have those restrictions been more punitive — and, often, unwarranted — than with specialtypharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. Every specialtypharmacy patient you serve should be monitored by a clinic pharmacist.
Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. drugpricing, reimbursement, and dispensing system. The 2022 Economic Report on U.S. The chart below illustrates the depth and breadth of the 2022 edition.
Let’s melt away this foul February with our monthly selection of scorching news from around the drug channel. In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialtypharmacy white bagging Let’s all follow the Buy-and-Bill Dollar!
Nowhere have those restrictions been more punitive — and, often, unwarranted — than with specialtypharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. Every specialtypharmacy patient you serve should be monitored by a clinic pharmacist.
Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. A single hospital can easily have five TPAs and 70 contract pharmacies. The Supreme Court voted unanimously to reverse 340B cuts.
The 340B DrugPricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialtypharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.
Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to $435 million in savings generated for the hospitals and health systems we serve. A single hospital can easily have five TPAs and 70 contract pharmacies. The Supreme Court voted unanimously to reverse 340B cuts.
General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare DrugPrice Negotiation Program (DPNP). Pharmacy benefit managers: transparency, accountability, and impact on patient care. Casalino, L.,
In their view, just as you wouldn’t separate drug therapies from medical care, pharmacy and medical benefits should be tightly integrated too. HealthPartners is a health solutions company providing care through hospitals and clinics, as well as insurance coverage for companies. And we agree.
Timely implementation is particularly critical for beneficiaries requiring immediate mental health or substance use treatment, where delays can lead to worsening health outcomes, increased hospitalization rates, and preventable mortality. Issue Brief: Improving Prescription DrugPrice and Cost Transparency. 2024.30.2.206.
I started my career in consulting implementing systems inside of a couple dozen different hospitals and then I went on to find Microsoft’s healthcare partner ecosystem. Even there, that’s impacted by some distortions around pbms and how hospitals radically markup those drugs, but that’s probably the one exception.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content